Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Triptans--why once?

Gal Ifergane1, Itzhak Wirguin, Pesach Shvartzman

  • 1Headache Clinic, Department of Neurology, Soroka Medical Center, Beer-Sheva, Israel.

Headache
|September 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physical activity in migraine: Identifying an engagement threshold and patient clusters in a population-based cohort.

Cephalalgia : an international journal of headache·2026
Same author

Acute Environmental Triggers and Intermediate-Term Modulators of Emergency Migraine-Related Health Care Encounters.

Neurology·2026
Same author

Migraine epidemiology, comorbidities and therapeutic landscape: a national population-based study.

Frontiers in neurology·2026
Same author

The association between migraine and glaucoma diseases: A retrospective cohort study.

Headache·2025
Same author

Response to "Optimizing triptan safety in emergency settings under cardiovascular risk uncertainty".

Headache·2025
Same author

Reinterpreting migraine in a societal evolutionary context.

Cephalalgia : an international journal of headache·2025
Same journal

Biochemical profiling and symptomatology of androgen deficiency in males with cluster headache: A prospective case-control study.

Headache·2026
Same journal

Thiamine deficiency in patients with chronic migraine: A case-control study.

Headache·2026
Same journal

Potential association of cluster headache with certain COVID-19 vaccines: An assessment from the pharmacovigilance databases.

Headache·2026
Same journal

Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series.

Headache·2026
Same journal

Adverse childhood experiences, migraine, and adverse pregnancy outcomes among teenage mothers.

Headache·2026
Same journal

Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study.

Headache·2026
See all related articles

Many migraine patients, particularly men and those outside of middle age, do not refill their triptan prescriptions after initial use. This suggests many do not continue triptan therapy for acute migraine attacks.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Triptans are 5HT(1B/1D) agonists effective for acute migraine relief.
  • They offer a safe and effective treatment for headache and associated symptoms.

Purpose of the Study:

  • To evaluate triptan utilization patterns.
  • Study conducted in a large Israeli HMO district.

Main Methods:

  • Retrospective review of computerized prescription data.
  • Included 1498 patients who filled their first triptan prescription between July 2003 and June 2004.

Main Results:

  • 841 patients (56.1%) purchased triptans only once within a 1-year follow-up.
  • Single-time triptan use was more common in men and patients younger than 30 or older than 70.

Related Experiment Videos

Conclusions:

  • A significant proportion of migraine patients discontinue triptan use after initial trial.
  • Suggests many patients may not continue triptan therapy following their first prescription.